Methods and conjugates are disclosed for alleviating toxicity(ies) associated with administration of immune-stimulatory conjugates, and in particular for alleviating toxicity(ies) associated with intravenous administration of such conjugates.

Compositions for the treatment of disease with immune stimulatory conjugates

Methods are provided for the adjuvant treatment of operable HER2-positive primary breast cancer in human patients by administration of pertuzumab in addition to chemotherapy and trastuzumab. The methods reduce the risk of recurrence of invasive breast cancer or death for a patient diagnosed with HER2-positive early breast cancer (eBC) compared to administration of trastuzumab and chemotherapy, without pertuzumab.

Adjuvant treatment of her2-positive breast cancer

Anti-mesothelin antibodies and conjugates comprising such antibodies are disclosed herein as well as the use of such conjugates in the treatment of disease, such as cancer.

Anti-mesothelin antibodies and immunoconjugates thereof

The present invention relates to a pharmaceutical composition including an anti-Her2 antibody and exhibiting excellent stability.

Liquid phase composition for antibody drug

The present invention relates to a liquid formulation comprising: a trastuzumab antibody or an antigen-binding fragment thereof; a stabilizer; and a surfactant, but not containing a buffering agent, and to a method for preparing same.

Trastuzumab antibody stabilizing formulation free of buffering agent

Fixed dose HER2 antibody formulations for subcutaneous administration are provided along with their use in the treatment of cancer. The formulations include fixed dose subcutaneous formulations of pertuzumab and subcutaneous co-formulations of pertuzumab and trastuzumab, and their use in the treatment of cancer.

Subcutaneous her2 antibody formulations

피하 투여를 위한 고정 용량의 HER2 항체 제형, 및 암의 치료에 대한 이들의 사용이 함께 제공된다. 상기 제형은 퍼투주맙의 고정 용량의 피하 제형 및 퍼투주맙 및 트라스투주맙의 피하 공동-제형을 포함하며, 암의 치료에 대한 용도를 갖는다.

Badovinac-Crnjevic Tanja

Papers

Subcutaneous her2 antibody formulations

피하 her 2 항체 제형